Triple Analysis: Melanoma, Prostate Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma report part comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 investigators, from Ceased to Marketed. This part extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

• Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
• Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
• Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
• Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
• Supporting development of integrative molecule, pathway and disease area strategies
• Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.